Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 4/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.51 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.51 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2031530 | 0.92 | PTK2 (0.55) | PTK2LRRK2JAK2NTRK1TYK2 | |
| SCHEMBL2031292 | 0.91 | PTK2 (0.66) | PTK2LRRK2JAK2NTRK1TYK2 | |
| SCHEMBL2038266 | 0.89 | PTK2 (0.53) | PTK2LRRK2JAK2NTRK1TYK2 | |
| SCHEMBL2036906 | 0.88 | PTK2 (0.54) | PTK2JAK2NTRK1TYK2KDR | |
| SCHEMBL2029891 | 0.88 | PTK2 (0.55) | PTK2LRRK2JAK2NTRK1TYK2 | |
| SCHEMBL2036362 | 0.87 | ALK (0.58) | PTK2LRRK2JAK2NTRK1TYK2 | |
| SCHEMBL2030567 | 0.87 | ALK (0.58) | PTK2LRRK2JAK2NTRK1TYK2 | |
| SCHEMBL2637895 | 0.85 | PTK2 (0.55) | PTK2LRRK2JAK2NTRK1TYK2 | |
| SCHEMBL2032789 | 0.85 | LRRK2 (0.55) | PTK2LRRK2JAK2NTRK1TYK2 | |
| SCHEMBL2032442 | 0.85 | PTK2 (0.55) | PTK2LRRK2JAK2NTRK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | PTK2 2/4885LRRK2 854/4885JAK2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.